TITLE

Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke

AUTHOR(S)
Foerch, C.; Curdt, I.; Yan, B.; Dvorak, F.; Hermans, M.; Berkefeld, J.; Raabe, A.; Neumann-Haefelin, I.; Steinmetz, H.; Sitzer, M.
PUB. DATE
February 2006
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Feb2006, Vol. 77 Issue 2, p181
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Biomarkers of stroke are an evolving field of clinical research. A serum marker which can differentiate between haemorrhagic and ischaemic stroke in the very early phase would help to optimise acute stroke management. Objective: To examine whether serum glial fibrillary acidic protein (GFAP) identifies intracerebral haemorrhage (ICH) in acute stroke patients. Methods: A pilot study assessing 135 stroke patients admitted within six hours after symptom onset. Diagnosis of ICH (n = 42) or ischaemic stroke (n = 93) was based on brain imaging. GFAP was determined from venous blood samples obtained immediately after admission, using a research immunoassay. Results: GFAP was detectable in the serum of 39 patients (34 of 42 (81%) with ICH, and five of 93 (5%) with ischaemic stroke). Serum GFAP was substantially raised in patients with ICH (median 11 ng/l, range 0 to 3096 ng/l) compared with patients with ischaemic stroke (median 0 ng/l, range 0 to 14 ng/l, p<0.001). Using receiver operating characteristic curve analysis, a cut off point of 2.9 ng/l provided a sensitivity of 0.79 and a specificity of 0.98 for the identification of ICH in acute stroke (positive predictive value 0.94, negative predictive value 0.91 ; p<0.001 ). Conclusions: Serum GFAP can reliably detect ICH in the acute phase of stroke. Further evaluation of the usefulness of GFAP as an early diagnostic marker of ICH is now required, with the aim of optimising cause specific emergency management.
ACCESSION #
20201124

 

Related Articles

  • Serum YKL-40 Levels Correlate with Infarct Volume, Stroke Severity, and Functional Outcome in Acute Ischemic Stroke Patients. Hyun Young Park; Chang-Duk Jun; Se-Jeong Jeon; See-Sung Choi; Hak-Ryul Kim; Dan-Bee Choi; Seongae Kwak; Hak-Seung Lee; Jin Sung Cheong; Hong-Seob So; Young-Jin Lee; Do-Sim Park // PLoS ONE;Dec2012, Vol. 7 Issue 12, p1 

    Background and Purpose: YKL-40 is associated with various neurological disorders. However, circulatory YKL-40 levels early after onset of acute ischemic stroke (AIS) have not been systematically assessed. We aimed to identify the temporal changes and clinical usefulness of measuring serum YKL-40...

  • Interleukin-18 in acute ischaemic stroke patients. Zaremba, J.; Losy, J. // Neurological Sciences;Oct2003, Vol. 24 Issue 3, p117 

    Abstract As proinflammatory cytokines released during ischaemia are detrimental to the brain, the study aimed to evaluate serum interleukin-18 (IL-18) levels in stroke patients and to investigate the relation between these and epidemiological and clinical data. The study comprised 23 ischaemic...

  • PLATFORM PRESENTATIONS: STROKE.  // Canadian Journal of Neurological Sciences;May2005 Supplement, Vol. 32, pS26 

    Presents abstracts of research works related to stroke. "Indolent course and late recurrence of isolated angiitis of the CNS," by Stanley Elysee and Daniela Toffoli; "Informed consent for thrombolysis in acute ischemic stroke- current dilemma," by V. Palumbo and C. Sivakumar; "Visualization of...

  • NXY 059: CPI 22, NXY 059G. Limited, Adis International // Drugs in R&D;2003, Vol. 4 Issue 4, p254 

    NXY 059 [CPI 22, NXY 059G], a nitrone with free radical trapping properties, has potential in the treatment of ischaemic stroke. NXY 059 is based on Centaur Pharmaceuticals' proprietary Nitrone-Related Therapeutics (NRT[sup â„¢]) technology. A generic form of NXY 059, NXY 059G, has been...

  • PLATFORM PRESENTATIONS: STROKE/PEDIATRIC STOKE.  // Canadian Journal of Neurological Sciences;May2005 Supplement, Vol. 32, pS16 

    Presents abstracts of research works related to stroke and pediatric stroke. "Intracranial giant cell vasculitis with cerebral amyloid angiopathy: An unusual combination," by J. Diggle and K. Heathcote; "Headache and migraine in children with stroke," by Melissa Martin and Trish Domi;...

  • Assessment and Explorations on the Mechanism of Neuroprotection of Patients in Ischemic Stroke by Traditional Chinese Medicine. Shen Si-yu; Fu Xiao-dong; Fei Zhen-yu // Chinese Journal of Integrative Medicine;Sep2005, Vol. 11 Issue 3, p237 

    Ischemic stroke is a common clinical emergency, with thrombolysis and neuroprotection as its cardinal treatment, and nowadays the latter is more and more stressed by stroke researchers. On the basis of pathophysiology and ischemic cascade of ischemic stroke, we now try to analyze the conceivable...

  • Clinical trials now enrolling patients with TIAs. Henry, Gregory L.; Johnston, S. Claiborne // Patient Care for the Nurse Practitioner;May2007, Vol. 10 Issue 5, p7 

    The article presents abstracts of medical research. They include "Natural History of Stroke: Cause and Development," "Carotid Revascularization Endarterectomy versus Stenting Trial (CREST)," and "Smoking Cessation Intervention After Stroke or Transient Ischaemic Attack."

  • Mild to Moderate Early Exercise Promotes Recovery from Cerebral Ischemia in Rats. Shi-Uk Lee; Dae-Yul Kim; Sung-Hye Park; Deok-Hyung Choi; Hee-Won Park; Tai Ryoon Han // Canadian Journal of Neurological Sciences;Jul2009, Vol. 36 Issue 4, p443 

    Objective: We examined the effects of various exercise intensities on recovery from middle cerebral artery occlusion (MCAO) in rats. Methods: First, we administered a 120-minute left MCAO to male Sprague-Dawley rats and randomly assigned them to one of four groups: no exercise (Group 1), mild...

  • Dissection of the brain supplying arteries over the life span. Ahl, B.; Bokemeyer, M.; Ennen, J. C.; Kohlmetz, C.; Becker, H.; Weissenborn, K. // Journal of Neurology, Neurosurgery & Psychiatry;Aug2004, Vol. 75 Issue 8, p1194 

    Cervical artery dissection (CAD) is being increasingly diagnosed due to improved neuroimaging methods. The mean age of patients with CAD is about 40 years, with a peak between 40 and 45 years of age. Proven data on the incidence of CAD in older patients are missing. Therefore, whether CAD should...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics